A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Inclusion Criteria: 1. Aged 18 to 75 years, regardless of gender; 2. Patients with ischemic heart failure with NYHA functional class III or IV after receiving the maximum tolerated dose of guideline-directed medical therapy (GDMT); 3. LVEF ≤ 35% as measured by cardiac MRI; 4. Coronary angiography meeting the indications for coronary artery bypass grafting (CABG) surgery; 5. Voluntary participation and signing of the informed consent form. Exclusion Criteria: Patients considered for this trial must not meet any of the following criteria: 1. Acute viral myocarditis; 2. Acute phase of myocardial infarction (≤ 3 months); 3. Cardiac amyloidosis; 4. Pericarditis; 5. Expected to undergo heart transplantation; 6. Suffering from a disease that restricts the motor system, making them unable to complete the 6-minute walk test; 7. Suffering from autoimmune diseases; 8. Estimated glomerular filtration rate (eGFR) \< 35 ml/min/1.73m², or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 100 U/L; 9. Presence of any untreated precancerous lesions or those requiring active monitoring; 10. Occurrence of malignant tumors within 5 years prior to screening; 11. Expected to undergo other concurrent cardiac surgeries (excluding ventricular aneurysm resection and left atrial appendage excision/ligation); 12. Having contraindications to the use of immunosuppressants; 13. Having contraindications to MRI; 14. Having contraindications to CABG surgery; 15. Females who are pregnant, lactating, or have a positive blood pregnancy test; 16. Plans to conceive within one year; 17. Having systemic diseases that are not effectively controlled; 18. Other conditions deemed unsuitable for participation in this clinical trial as evaluated by the investigator.